Katakam and co-workers have not shown SSRIs to be harmful and ineffective and should stop claiming that they have

Author:

Hieronymus FredrikORCID,Lisinski Alexander,Näslund Jakob,Eriksson Elias

Abstract

Funded by the Danish state to provide guidance in health-related matters, the Copenhagen Trial Unit (CTU) at Rigshospitalet may cause considerable societal harm if allowing their analyses to be influenced by bias and prejudice rather than rigor and impartiality. This is why we found it worthwhile to comment on a report from the CTU in which the authors invoked analyses marred by numerous errors and methodological mistakes to claim that selective serotonin reuptake inhibitors (SSRIs) are harmful and ineffective. The CTU group has now produced a response to our comment which is on par with their original contribution in terms of bias, misconceptions and mistakes. Our conclusion is that the reputation of the CTU would be best served by the authors asking for retraction of their SSRI paper.

Publisher

Cambridge University Press (CUP)

Subject

Biological Psychiatry,Psychiatry and Mental health

Reference55 articles.

1. Pharmacia&Upjohn. Reboxetine (PNU-155950E) versus placebo and fluoxetine in a controlled, randomized, double-blind, multicenter study of treatment in major depressive disorders: final report of the study protocol 97-CRBX-050, 2001. Available at http://www.iqwig.de/download/Studie_050.pdf. Accessed April 5, 2018.

2. U.S. Food and Drug Administration CfDEaR. Statistical review – Lexapro NDA 021323, 2001. Available at http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Statr.pdf. Accessed April 5, 2018.

3. Multicenter, Placebo-Controlled, Fixed-Dose Study of Citalopram in Moderate-to-Severe Depression

4. Pharmacia&Upjohn. Reboxetine, placebo, and paroxetine comparison in patients with major depressive disorder: a phase III, randomized, double-blind, placebo- and active-treatment-controlled, parallel-group, 8-week study of reboxetine, given orally twice daily to adult patients with major depressive disorder: final report of the study protocol M/2020/0047, 2001. Available at http://www.iqwig.de/download/Studie_047.pdf. Accessed April 5, 2018.

5. EliLilly. Clinical Study Summary: Study F1J-MC-HMATa, 2004. Available at https://assets.contentful.com/hadumfdtzsru/1D76MTikKkeSIuOS4SgQcq/433330f08ad190a430f5d0f2140cb4b3/Duloxetine-F1J-MC-HMAT-_Study-Group-A_.pdf. Accessed April 5, 2018.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Good news regarding SSRI safety in Danish meta-analysis;Acta Neuropsychiatrica;2019-12-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3